Leptin, the adipokine produced mainly by the white adipose tissue, plays important roles not only in the regulation of food intake, but also in controlling immunity and inflammation. It has been widely demonstrated that the absence of leptin leads to immune defects in animal and human models, ultimately increasing mortality. Leptin also regulates inflammation by means of actions on its receptor, that is widely spread across different immune cell populations. The molecular mechanisms by which leptin determines its biological actions have also been recently elucidated, and three intracellular pathways have been implicated in leptin actions: JAK-STAT, PI3K, and ERK 1/2. These pathways are closely regulated by intracellular proteins that decrease leptin biological activity. In this review, we discuss the molecular mechanisms by which leptin regulates immunity and inflammation, and associate those mechanisms with chronic inflammatory disorders. Arq Bras Endocrinol Metab. 2012;56(9):597-607 Keywords Leptin; immunity; inflammation; cytokines SUMÁRIO A leptina, uma adipocina produzida principalmente pelo tecido adiposo branco, tem um papel importante não somente na regulação da ingestão alimentar, mas também no controle da imunidade e da inflamação. Já foi amplamente demonstrado que a ausência de leptina causa deficiências imunológicas em modelos animais e em humanos, levando ao aumento da mortalidade. A leptina também regula a inflamação por meio da ação em seu receptor, amplamente distribuído em diversos tipos de células do sistema imunológico. Os mecanismos moleculares pelos quais a leptina determina suas ações biológicas foram recentemente elucidados, e três cascatas intracelulares são ativadas pela leptina: JAK-STAT, PI3K e ERK 1/2. Essas cascatas são reguladas por proteínas intracelulares, reduzindo as ações da leptina. Nesta revisão, são discutidos os mecanismos moleculares pelos quais a leptina regula a imunidade e a inflamação, associando-os a enfermidades inflamatórias crônicas. Arq Bras Endocrinol Metab. 2012;56(9):597-607 Descritores
INTRODUCTION
A lthough initially considered as a simple storage of fat, overwhelming evidence led the adipose tissue to be conceptualized as an endocrine organ (1, 2) . The discovery of leptin has dramatically changed the under standing of the physiological importance of the adipose tissue, making it clear that the adipose tissue synthe sizes and releases this key hormone that plays a crucial role to signal the brain to control food intake and ener gy expenditure (3) . From this seminal discovery to the present, it has been shown that the adipose tissue not only synthesizes and releases dozens of other metabo licrelated factors, such as resistin and adiponectin, but it is also a source of cytokines and immune factors such as tumornecrosis factor alpha (TNFa), interleukin1 (IL1) alpha (IL1a), IL1β, IL1 receptor antagonist (IL1RA), and IL6 (1) . All of these findings attracted attention to fat as an immunoendocrine organ that inte racts with several physiological systems of the organism.
Leptin is a cytokine produced predominantly by the differentiated white adipose tissue, with various func tions in the immune and endocrine systems, including reproduction, glucose homeostasis, hematopoiesis, an giogenesis, osteogenesis, wound healing, and inflam mation (4) . This hormone regulates caloric expenditure and intake, playing a central action in energy balance (5) . Leptin levels are directly correlated with fat mass and are elevated in obese patients, who are also leptin resistant. Leptindeficient mice and humans are severely obese and have several metabolic and endocrine altera tions, such as hyperglycemia, insulin resistance, hyper triglyceridemia, hypogonadotropic hypogonadism, and central hypothyroidism (6, 7) .
Leptin plays a major role in the chronic proinflam matory state that is seen in obesity, metabolic syndrome, and their complications, such as atherosclerosis (8) . By acting on the long isoform of the leptin receptor (Ob R), which is expressed by different immune cell types, leptin triggers inflammatory responses. Concomitantly, certain inflammatory and infectious stimuli, such as IL 1, lipopolysaccharide (LPS), and TNFa can also in crease leptin levels (9), which correlate with the level of inflammation. Therefore, the interactions between leptin and inflammation are bidirectional: proinflam matory cytokines increase the synthesis and release of leptin, which in turn helps to perpetuate the loop of chronic inflammation in obesity.
In this manuscript, we summarize the role of leptin in the immune system, the molecular links between leptin and inflammation, and the relationships between leptin and chronic inflammatory diseases.
Molecular mechanisms of leptin and modulation of immune cells
During states of normal nutrition, leptin signals to the brain that excess energy is available for several biological processes, including immune response. Under energe tic restriction, leptin levels are low, and immune respon se is impaired. Leptin exerts a link between the T helper (Th) 1 immune response and nutritional status, and inadequate body weight -both obesity and malnutri tion -can importantly influence immune cell function, both in innate and adaptive immune responses (10) .
Leptin has structural homology with the cytokines of the longchain helical family that includes IL6, IL 11, IL12, and oncostatin M. Leptin receptor, ObR, has structural similarities with the members of the class I cytokine receptor (gp130) superfamily, which in cludes the receptor for IL6, leukocyte inhibitory factor (LIF), and granulocyte colonystimulating factor (G CSF). The ObR is expressed by neutrophils, mono cytes, macrophages, subpopulations of T cells and B cells, mast cells, dendritic cells (DC), and natural killer (NK) cells (11) . There are at least six different isoforms of the leptin receptor in rodents; ObRa, ObRb, Ob Rc, ObRd, ObRe, and ObRf; these are all pro ducts of six alternatively spliced forms of the ObR gene (12) . Of all of these isoforms, ObRb is the only long form, which contains a prominent cytoplasmic region containing several motifs required for signal transduc tion and is capable of activating the JAK-STAT path way. There are four truncated (short) forms, including ObRa, ObRc, ObRd, and ObRf, of which ObRa is regarded as a leptin transporter across the bloodbrain barrier and a leptin degrader; and a secreted form (Ob Re) that lacks both the intracellular and transmembrane domains, and serves as a plasmatic leptinbinding pro tein. These isoforms are involved in mediating leptin actions in the brain and peripheral organs. All isoforms, with the exception of ObRb, share the same identical extracellular, ligandbinding domains, but differ at the C terminus. Only ObRb has a long cytoplasmic region containing several motifs required for signal transduc tion, whereas the others have transmembrane domains, and lack some or all of these motifs. Transduction sig naling takes place by activation of conserved box 1 and box 2 motifs (intracellular amino acids 617 and 49 60, respectively). Cytokine receptor homology module 2 (CRH 2) is the main binding site for leptin on the ObR. The immunoglobulinlike domain (Iglike) and fibronectin III domain (FNIII) are critically involved in ObR activation. The role of CRH1 remains to be determined.
The elucidation of leptininduced second messen ger pathways is marked by two fundamental factors: 1) leptin tridimensional structure and 2) leptin resistance to perform as an antiobesity hormone in obese/over weight nonleptin deficient individuals. First, although the cloning of the Ob gene revealed no significant se quence homology with any other known protein, com putationalbased research studies predicted that leptin displayed tridimensional characteristics of a fourhelix bundled cytokine, such as those that activate the JAK STAT pathway (Figure 1 ) (13) . Moreover, the cloning of the OB-R gene reported towards the end of 1995 (12) revealed that leptin receptor shared sequence ho mology with gp130, the signal transducing unit of the IL6 receptor that signals via the JAKSTAT pathway. The structural similarities that leptin and the OB-R gene share with the IL6 cytokine family lead to func tional in vitro signaling studies that proved that leptin activated the JAKSTAT pathway (14) . In vivo studies carried out in mice have shown that peripheral adminis tration of leptinactivated hypothalamic STAT3 in ob/ ob and WT mice, but not in db/db mice, indicating that the presence of a functional OB-R gene was required for leptininduced STAT3 activation within the brain.
Leptin controls other two key signaling path ways, namely the extracellular signalregulated ki nase (ERK)1/2 (Figure 2) , and the activation of the phosphatidylinositol3kinase (PI3K) (Figure 3 ) (15) . Janusactivated kinase phosphorylation of Tyr 985 (or phosphorylated JAK2 itself, independent of phosphor ylated Tyr 985 ) leads to recruitment and phosphoryla tion of SHP2 (src homology 2containing tyrosine phosphatase). Then, phosphorylated SHP2 activates the ERK signaling pathway via growth factor recep tor binding2 (GRB2) (16) . The ERK/MAPK path way is believed to be the main mechanism involved in regulatory T (T reg ) cell regulation (11) , by controlling the promoters for the transcription of c-fos, jun and egr-1 genes, fundamental in cell proliferation and dif ferentiation (17) . The ERK/MAPK pathway can be activated by both ObRa and ObRb leptin recep tors. It shares many similarities with the JAK2/STAT3 pathway as JAK2 is required for phosphorylation of the SH2domain containing protein tyrosine phosphatase (SHP2) via pathways both dependent and indepen dent of Tyr 985 (18) . There is also one pathway that occurs independently of phosphorylation at tyrosine sites on ObRb, lead ing to the activation of phosphatidylinositol 3'kinase (PI3K). This pathway originates with JAK2 autophos phorylation, which leads to the recruitment and phos phorylation of insulin receptor substrate (IRS) proteins. Then, phosphorylated IRS proteins recruit phosphati dylinositol 3'kinase (PI3K) and activate downstream signals (15) . . STAT-3 then undergoes dimerization and translocates into the cell nucleus to function as a promoter for gene transcription [4] . Members of the SOCS family (SOCS1 and SOCS3) suppress the action of leptin by binding to JAK 2 and tyrosine residues. The PI3K pathway is an acute phase contributor of inflammation, in contrast to JAK2/STAT3, which is a slower process as it functions by altering gene tran scription (15) . Both JAK2 and the insulin receptor participate in the phosphorylation of IRS, which then stimulate the p85 subunit of PI3K, thereby activat ing it. Once activated, the main mechanism of action of PI3K is intracellular phosphorylation of proteins. The chain of events involve phosphorylation of PtdIns 4,5diphosphate (PIP2) to form PtdIns 3,4,5triphos phate (PIP3) (19) . Phosphatase and tensin homologue (PTEN) is an antagonist of this pathway and fosters the conversion of PIP3 back to PIP2 ( Figure 3 ) (19) . PIP3 is a key activator of phosphoinositidedependent kinase 1 (PDK1), which has many downstream effects, espe cially in regulating protein kinase B (Akt). Akt is a key participant in regulating neuropeptide Y and nitric ox ide (NO) mTOR via p70S6K (19) . The PI3K pathway has also been implicated in controlling the Rho family of GTPases, which regulate apoptosis and remodel the actin skeleton within cells (15, 19) .
Soon after leptin discovery, it became evident in pre clinical and clinical experiments that obese rodents and humans displayed leptin resistance. Thus, the search for the putative mechanisms leading to leptin resistance was taking place. In the mid90s, a new family of cytokine induced intracellular signaling inhibitors of the JAK STAT pathway were identified, namely the supressors of cytokine signaling (SOCS 13) (20) . SOCS3 plays a key role in providing negative feedback to this pathway, as it binds to Tyr 985 and JAK2 to prevent phosphory lation of SHP2, thus stopping the cascade. It is also believed to repress the activity of SHP2 (21) . Since leptin also operates via JAKSTAT, Bjorbaek and cols. hypothesized that activation of SOCS genes could con tribute to leptin resistance (22) . They demonstrated that peripherally administrated leptin rapidly increased the induction of hypothalamic SOCS3 in areas that are relevant for the control of food intake and ener gy expenditure. Moreover, they showed that SOCS3 was involved in negative regulation of leptininduced intracellular signal transduction. In rodent models, it was shown that SOCS3 could also be involved in leptin resistance that occurs during the aging process, and that lack of SOCS3 within the brain was effective to increase leptin sensitivity and to prevent dietinduced obesity (23) .
Another intracellular mechanism that was shown to control leptin resistance is orchestrated by protein tyrosine phosphatase 1B (PTP1B) (24) . This phospha tase acts by dephosphorylating JAK2 and, therefore, it prevents JAK2induced phosphorylation of the leptin receptor (24) . Moreover, similar to mice deficient in SOCS3, neuronal deletion of PTP1B increased leptin and insulin sensitivity, preventing body weight gain in a dietinduced obesity animal model (25) . Similar findings were previously shown in wholebody PTP1B knockout studies (26) .
Leptin and innate immunity
Leptin binds to its receptor in macrophages and mo nocytes, improving phagocytosis by regulating oxidati ve stress. It also induces eicosanoid and nitric oxide syn thesis, acts as a chemoattractant, increases the secretion of cytokines, such as IL1RA, IL1, IL6, TNFa, and CCchemokine ligand, and prevents apoptosis (27) . It also dosedependently increases the proliferation of cir culating cells, and stimulates the expression of activa tion markers, such as CD69 and CD25, among others (28) . The increased number, and the activation of mo nocytes by the phorbol12 myristate 13acetate (PMA) or LPS is synergistically improved by leptin (29) . Lep Stimulation of Ob-Rb promotes phosphorylation of Tyr985 by JAK2. Both these units can phosphorylate SHP-2, which further modulates GRB2 and activates ERK1/2 of the MAPK family. ERK1/2 promotes the transcription of the c-fos and egr-1 genes. SOCS3 is an inhibitor of this pathway, with a mechanism similar to the JAK2/STAT3 pathway. tin also activates macrophages by means of the mam malian Target of Rapamycin (mTOR) kinase pathway, which is an intracellular nutrientresponsedependent pathway that integrates growth factor and nutrientde rived signals to cellular growth rates, controlling cell growth and division. Leptin stimulates phagocytosis by stimulating phospholipase and increasing the produc tion of leukotriene B4, eicosanoids, NO, cholesterol acyltransferases1, and cyclooxygenase 2 (30) . Leptin also increases the production of growth hormone by means of PKC and NOdependent pathways (31) . Leptin acts on several other immune cells. On eosi nophils, it induces the expression of adhesion molecules and CD18, increases chemokinesis, and stimulates the release of inflammatory cytokines IL1β, IL6, IL8, growthrelated oncogenea, and monocyte chemoat tractant protein1 (MCP1), which is a known chemo attractant for monocyte/macrophage infiltration (32). On DC, leptin increases the expression of cytokines, such as IL6 and TNFa; surface molecules, such as CD1a and CD80; and reduces apoptosis rates. Leptin also induces morphological and functional changes wi thin DC, directing them towards Th1 priming (33) . Mast cells also express ObR, and it is probable that leptin acts on them both in a paracrine and/or auto crine fashion (34) . On polymorphonuclear cells, leptin induces chemoattraction and the production of reac tive oxygen species (ROS) via mechanisms that might involve interaction with monocytes (35) . Finally, leptin contributes to NK cell development, differentiation, activation, proliferation, and cytotoxicity (35) .
Leptin and adaptive immunity
Leptin maintains the thymic parenchyma via its direct antiapoptotic effects on T cells by stimulating the me dullary thymic epithelial cell expression of IL7, a thy mocyte growth factor (36) . Moreover, leptin affects the activation of T lymphocytes. Hypoleptinemia caused by starvation leads to thymic atrophy and higher fre quency of infections, and exogenous recombinant lep tin prevents the reduction in cortical doublepositive CD4 + CD8
+ thymocyte subpopulation (37) . However, leptin can only induce the proliferation and activation of mature human peripheral blood lymphocytes if it is coadministered with other general immunostimulants, such as concanavalin A (ConA) or phytohemagglutinin (PHA) (36) . Importantly, the effect of leptin on lym phocyte proliferation is specific to different subpopu lations. It inhibits the proliferation of memory T cells (CD4+CD45RO+), but stimulates the proliferation of naive T cells (CD4+CD45RA+). This means that leptin polarizes Th0 cytokine production towards a proin flammatory (Th1, TNFa, IFNγ IL2, IL12, and leptin itself), rather than antiinflammatory phenotype (Th2, IL4, IL10) (38) . It seems that leptin acts directly on circulating T lymphocytes when they are costimulated, since this effect is observed even in the lack of monocytes (38) (27) .
Furthermore, leptin is able to reduce the human CD4+CD25+ T reg cells, which are a small subset of CD4+ T cells that control the peripheral immune tole rance, and prevent inappropriate immune responses, such as allergy and autoimmunity. Commonly, T reg cells influence the activities of cells of the innate immune system and modulate effector T cell responses. In ani mal models of chronic leptin and ObR deficiencies, the percentage, absolute number, and activity of T reg cells is increased, resulting in resistance to autoimmune diseases. When leptin is replaced, the number of T reg cells returns to the same levels found in WT mice. In humans, leptin has a similar effect on T reg cells. Interest ingly, freshly isolated T reg cells can produce significant quantities of leptin, and express high density of the Ob R, which constrain their proliferation (28) .
Besides the effects on CD4+ T cells, leptin adminis tration can stimulate the proliferation of B lympho cytes, NKT and CD8+ T cells, and increase cytokine responsiveness. The interactions between leptin and cy tokines are bidirectional, and both stimulate each other (Figure 3 ). Table 1 summarizes the leptin effects on innate and adaptive immunity.
LEPTIN AND CLINICAL CONDITIONS Congenital deficiency of leptin
In humans, congenital leptin deficiency (40) or leptin receptor mutation (41) lead to increased vulnerability to infections with elevated risk of death during chil dhood. Congenital deficiency of leptin is associated with a decrease in CD4 + T cell numbers, and an increase in CD8+ T and B cells, as well as a pronounced reduction in the number of naive T cells, and an increase in me mory T cells. In addition, lymphocytes exhibit impaired proliferative response and reduced production of cytoki nes in response to several stimuli, with abolishment of IFNγ secretion, and a prevailing Th2 cytokine pheno type (40) . However, these immune defects are not an obligatory characteristic of patients with mutation in the leptin gene, in whom the immune profile possibly de pends on the genotype and genetic expressivity (42) . In leptindeficient children, leptin treatment increased pro liferation and cytokine response, particularly of IFNγ levels, increased number of leukocytes, and improved recurrent dermatites and asthmatic crises (43) .
Patients with leptinreceptor mutation present less prominent immune alterations than patients with con genital leptin deficiency (41) . A reduction in the num ber and function of CD4+ T cells, a decrease in cytokine production after antigenic charge, and a compensatory in crease in the number of B cells have been described. These alterations are also restored with leptin replacement (41).
Hypoleptinemic states
Malnutrition or caloric deprivation produces immu nossupression in humans and animals. Acute hypolep tinemia caused by starvation is associated with reduced development of B cells in the bone marrow, and decre ased Tlymphocyte subpopulation with impairment of delayedtype hypersensitivity responses and thymic atro phy. These effects are more pronounced in patient sub mitted to chronic exposure to hypoleptinemia, and are prevented by replacement with exogenous leptin (44) .
Women with hypothalamic amenorrhea due to chronic caloric restriction (e.g., strenuous exercise or low body weight) present hypoleptinemia and low le vels of soluble TNFa receptor that are normalized by the treatment with rmetHuLeptin (recombinant me thionyl human leptin) (45) .
Congenital or acquired severe lipodystrophy is cha racterized by an almost complete lack of adipose tissue and low leptin levels. In general, these patients exhibit measurable abnormalities in immune markers at baseli ne, such as a higher percentage of B cells and reduction in TNFa production by peripheral blood mononuclear cells. Leptin replacement can increase CD4, CD8T, and NKT cell numbers, correct the disproportion of B cells, and improve TNFa release to physiological levels. Ho wever, patients with severe lipodystrophy surprisingly do not show clinical immune deficiency, and may present autoimmune diseases including autoimmune hepatitis, thyroidopathies, nephropathies, and type 1 diabetes (46).
Hyperleptinemic states: obesity and metabolic syndrome
Obesity, especially visceral adiposity, is considered an inflammatory disease, since the adipose tissue is able to produce inflammatory cytokines or collaborate with their production by other tissues (2) . Also, obese pa tients exhibit higher level of inflammatory markers such as Creactive protein, TNFa, IL6, IL18, MIF (macrophage migration inhibitory factor), haptoglo bin, SAA (serum amyloid A), and plasminogen acti vator inhibitor1. Furthermore, type 2 diabetes, athe Hyperleptinemia is correlated with proinflamma tory responses and with the chronic subinflammatory state observed in obesity. On the one hand, leptin en hances the production of inflammatory cytokines, and on the other hand, cytokines such as IL6 and TNFa promote leptin production by the adipose tissue as well. Increased leptin resistance associated with high levels of free fatty acid and inflammatory cytokines may contribute to the reduction in lipid oxidation in insu linsensitive organs, leading to accumulation of lipids (lipotoxicity) and insulin resistance (47) .
Moreover, leptin induces cholesterol uptake by mac rophages, angiogenesis, platelet aggregation, stimulates the oxidative stress in endothelial cells and inhibits va sorelaxation, increasing the risk of atherosclerosis (48) . Indeed, ob/ob mice are resistant to atherosclerosis de spite all the metabolic risk factors, whereas apolipopro tein Edeficient mice develop atherosclerosis if treated with leptin (49) .
In humans, leptin is an independent risk factor for coronary artery disease, and its levels are correlated with Creactive protein, plasma triglycerides, and fast ing plasma glucose levels (50) . Leptin is associated with insulin resistance and metabolic syndrome independent of obesity via central obesity, possibly by impairment of insulin signaling at the insulin receptor substrate1 phosphorylation (51) . Leptin is increased in patients with metabolic syndrome, but relative hypoleptinemia may be observed in cases of severe metabolic syndrome, possibly due to adipose tissue dysfunction (52) .
Leptin and acute inflammation
Leptin regulates the production of proinflammatory cytokines such as tumor necrosis factor alpha (TNFa), interleukin 1 (IL1), and interleukin (IL6). These cytokines also regulate the expression of leptin, which sustains a chronic proinflammatory state (Figure 4) .
Many genes related to inflammation, including ge nes encoding acute phase response proteins such as tPA (tissue plasminogen activator), fibrinogenβ, lipoca lin2, PAP1, preprotachykinin, and MnSOD (manga nese superoxide dismutase) are induced by leptin (53) . Leptin levels rapidly increase in acute inflammatory conditions, such as cholecystectomy, acute infection, and sepsis, particularly favored by cytokines, such as TNFa, IL6, and IL1β (36) . Parenteral administra tion of LPS, commonly used to experimentally induce systemic inflammation, leads to a rise in plasma leptin.
A protective role of leptin in the clearance of pathogens is observed in leptindeficient ob/ob mice, which deve lop severe disease and die of infection with Klebsiella more rapidly than WT mice. The ob/ob mice are also hi ghly susceptible to LPSinduced lethality, which can be reversed by the administration of leptin. The protective effects of leptin in these cases seem to occur by means of a modulation of TNFa and IL6 responses after en dotoxin priming (10) . Leptin upregulates the production of pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-a), interleukin 1 (IL-1), and interleukin (IL-6). These cytokines increase the expression of leptin mRNA, which subsequently sustains production of leptin. This is thought to be the mechanism for chronic inflammation. Elevated levels of leptin are found in sepsis and may be predictive of the severity of sepsis and increased sur vival (54) . Leptin is a critical factor in host resistance and in its absence, sepsisinduced organ damage is increased, whereas neutrophil function is diminished. Furthermore, there is an important role of leptin in the central nervous system (CNS) in regulating survival and systemic im mune response in sepsis. Selective leptin administration into the CNS controls systemic immune response in a functionally relevant manner with significant protection from sepsis. A leptindependent neurocircuit in the CNS is required for efficient coordination of the immune re sponse in sepsis to limit organ damage and prevent mor tality (38) . On the other hand, some studies have not found increased leptin levels in specific inflammatory conditions, including acute experimental endotoxemia in humans, HIV infection, and newborn sepsis (30) .
Leptin in chronic inflammatory diseases
Together with the established function of leptin as a pro inflammatory cytokine that helps the host fight infection, there is increasing evidence of an association bet ween lep tin and increased risk of both chronic inflammatory and autoimmune disease. Serum leptin levels are elevated in many chronic inflammatory conditions (Table 2 ). In ex perimental animal models, the investigation of the effects of leptin on the susceptibility to autoimmunity has clearly indicated that leptin can promote autoreactivity. Addi tionally, leptindeficient ob/ob mice and leptin receptor deficient db/db mice are resistant to the development of several experimentallyinduced autoimmune diseases.
tal models of arthritis, ob/ob and db/db mice exhibited less severe disease, with lower levels of IL1β and TNFa in the synovial liquid, and T cells presented decreased pro liferative response induced by the antigen and a shift to ward a Th2 cytokine profile. On the other hand, clinical studies have reported controversial results when address ing the relationship between plasmatic and synovial leptin levels versus the activity or severity of the disease.
Leptin is involved in the pathogenesis of osteoar thritis via the production of matrix metalloproteinases and type 2 nitric oxide synthase. Moreover, the carti lage of patients with osteoarthritis present higher pro duction of leptin. Also, high leptin levels have been re ported in patients with systemic lupus erythematosus in whom the elevated leptin levels were positively corre lated with atherosclerosis and inflammatory biomarkers of atherosclerosis.
Leptin levels increased just before the commence ment of hyperglycemia and diabetes in spontaneous au toimmune nonobese diabetic (NOD) mice, a model of type 1 diabetes. In addition, exogenous administration of leptin to these animals enhanced interferonγ production by Tcells, and expanded the autoimmune destruction of βcells, suggesting a possible proinflammatory influence of leptin on Th1 cells in this disease. Children with gre ater weight gain in the first year of life were more prone to develop type 1 diabetes in concordance with the evi dence that overnutrition and increased postnatal growth may be related to development of autoimmunity.
High levels of leptin were reported during acute exacerbations of chronic obstructive pulmonary dise ase, and were associated to serum IL6 and TNFa. Leptin is important to airway hyperresponsiveness as sociated with obesity, by the stimulation of cytokine and chemokine production in the lungs, but just in conjunction with other inflammatory agents and in su praphysiological levels.
Leptin may also be important in the cognitive im pairment observed in obesity and high fat diet, by means of inflammatory and oxidative pathways in microglia cells. Finally, it been suggested that leptin may be a link between adipose tissue and psoriatic inflammation. References (11, 55, 56) summarize the roles of leptin on different chronic inflammatory diseases.
Leptin as an anti-inflammatory cytokine
Leptin may be protective against type 1 diabetes by re ducing virusinduced insulitis (57) . Besides, exogenous leptin may exert an antiinflammatory role in the exo In human studies on multiple sclerosis (MS), it has been reported that the secretion of leptin is increased in both the serum and the cerebrospinal fluid (CSF) of naive patients with MS. This positively correlates with the se cretion of IFNγ in the CSF, and inversely correlates with the percentage of circulating T reg cells. Moreover, the in crease of leptin in the CSF is higher than in the serum, suggesting possible secondary in situ synthesis of leptin in the CNS and/or an increased transport across the blood brain barrier following enhanced systemic production.
Patients affected by Crohn's disease exhibit in creased visceral adiposity with hypertrophic mesenteric fat, independent of the body mass index. In these pa tients, it was observed an overexpression of both leptin mRNA and leptin protein by the hypertrophic mesen teric fat, suggesting an inflammatory role of leptin.
In rheumatoid arthritis, leptin plays an important ef fect by increasing Th1 cytokine expression. In experimen crine pancreas, protecting rats against acute pancreatitis mediated by the nitric oxide pathway (58) .
Leptin also played an antiinflammatory effect in an experimental model of acute colitis via a neutro phildependent mechanism that depends on the HPA (hypothalamicpituitaryadrenal) axis (59) . Another study showed that endogenous leptin may locally pro tect the joints from the most severe form of erosive rheumatoid arthritis in humans (60) . Table 2 summa rizes the role of leptin in clinical conditions.
CONCLUSIONS
Leptin plays a major role in the regulation of the im mune system. It has a positive effect on thymocytes, leading to an overall increased level of T cells, and inhi bits the transformation of naive T cells into Th2 cells, which are antiinflammatory. Additionally, leptin in creases macrophage and monocyte proliferation rates, thereby increasing the levels of inflammatory cytokines (TNFa, IL1, IL6) ( Figure 5 ). The absence of leptin leads to immune defects that ultimately translate into increased mortality due to infections. It is also a ma jor regulator of inflammatory response, with mainly proinflammatory actions. In excess, commonly seen in states of excess adiposity, leptin has been associated with several diseases where inflammation plays an im portant role in morbidity, such as cardiovascular disea ses, rheumatoid arthritis, and cancer.
Leptin acts by activating its receptor, which in turn trig gers different molecular pathways, namely the JAKSTAT, PI3K, and ERK/MAPK pathways. Within these path ways, several molecules modulate their activation, such as SOCS3. Better understanding of the molecular mecha nisms by which leptin regulates immunity and inflamma tion might lead to the development of therapeutic targets to treat diseases associated with leptin deficiency or excess.
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